Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
13,800
Employees13,800
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
13,800
Employees13,800

ZTS Key Statistics

Market cap
63.85B
Market cap63.85B
Price-Earnings ratio
24.79
Price-Earnings ratio24.79
Dividend yield
1.34%
Dividend yield1.34%
Average volume
3.08M
Average volume3.08M
High today
$144.57
High today$144.57
Low today
$142.55
Low today$142.55
Open price
$143.14
Open price$143.14
Volume
3.36M
Volume3.36M
52 Week high
$193.49
52 Week high$193.49
52 Week low
$139.34
52 Week low$139.34

ZTS News

Simply Wall St 17h
Zoetis: Valuation in Focus as Lenivia Approval Expands Animal Health Portfolio

Zoetis (ZTS) just secured Health Canada’s approval for Lenivia, a monoclonal antibody therapy that provides three months of pain relief from osteoarthritis in d...

Zoetis: Valuation in Focus as Lenivia Approval Expands Animal Health Portfolio
Simply Wall St 2d
How Investors Are Reacting To Zoetis Winning Canadian Approval for Lenivia Osteoarthritis Therapy

Zoetis Inc. recently announced that Health Canada has approved Lenivia, a monoclonal antibody therapy offering three months of pain relief from osteoarthritis i...

How Investors Are Reacting To Zoetis Winning Canadian Approval for Lenivia Osteoarthritis Therapy
Simply Wall St 3d
Assessing Zoetis After Recent FDA Approval and Share Price Slide in 2025

Thinking about Zoetis and whether to hang on, buy more, or move on? You are far from alone; the stock has made some surprising moves lately and investors everyw...

Assessing Zoetis After Recent FDA Approval and Share Price Slide in 2025

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
23.8%
Sell
0%

More ZTS News

TipRanks 4d
Zoetis announces Health Canada approval for Lenivia

Zoetis (ZTS) announced that Health Canada has approved Lenivia for the alleviation of pain associated with osteoarthritis in dogs. Elevate Your Investing Strat...

TipRanks 6d
Zoetis’s Strategic Launch of Innovative Monoclonal Antibodies for Osteoarthritic Pain Management

Analyst Michael Ryskin of Bank of America Securities maintained a Buy rating on Zoetis, with a price target of $200.00. Elevate Your Investing Strategy: Take ad...

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.